Wntresearch AB, of Stockholm, and The Sage Group plc, of Newcastle Upon Tyne, England, will collaborate to identify and engage potential partners before the phase II readout of Foxy-5, a synthetic hexapeptide with a formylated N-terminus, as neo-adjuvant therapy in subjects with Wnt-5a low colon cancer. The clinical trial is set to end in March 2022. Sage specializes in strategy and negotiations for research companies.